Wird geladen...
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spalt‐like tr...
Gespeichert in:
| Veröffentlicht in: | EMBO Mol Med |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6895605/ https://ncbi.nlm.nih.gov/pubmed/31657150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910638 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|